Form 4 Viatris Inc For: Aug 15 Filed by: Enrietti Andrew

Tue, 18 Aug 2026 18:01:00 -0400

si-local-file:///var/storage/secattach/20260818/26945703.html

Form 4 Viatris Inc For: Aug 15 Filed by: Enrietti Andrew

Tue, 18 Aug 2026 18:01:00 -0400

si-local-file:///var/storage/secattach/20260818/26945703.html

Form SCHEDULE 13G/A Viatris Inc Filed by: DAVIS SELECTED ADVISERS

Wed, 12 Aug 2026 12:00:00 -0400

si-local-file:///var/storage/secattach/20260812/26911188.html

Form SCHEDULE 13G/A Viatris Inc Filed by: DAVIS SELECTED ADVISERS

Wed, 12 Aug 2026 12:00:00 -0400

si-local-file:///var/storage/secattach/20260812/26911188.html

Viatris Inc (VTRS) spreader of August 17 and January 15 puts

Wed, 12 Aug 2026 06:26:19 -0400

Viatris Inc (NASDAQ: VTRS) 30-day option implied volatility is at 28; compared to its 52-week of 26 to 79 with a focus on a spreader of August 17 and January 15 puts.

Form 10-Q Viatris Inc For: Jun 30

Thu, 06 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260806/26883631.html

Form 10-Q Viatris Inc For: Jun 30

Thu, 06 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260806/26883631.html

Form SCHEDULE 13G Viatris Inc Filed by: FMR LLC

Thu, 06 Aug 2026 10:44:00 -0400

si-local-file:///var/storage/secattach/20260806/26881423.html

Form SCHEDULE 13G Viatris Inc Filed by: FMR LLC

Thu, 06 Aug 2026 10:44:00 -0400

si-local-file:///var/storage/secattach/20260806/26881423.html

Form 8-K Viatris Inc For: Aug 06

Thu, 06 Aug 2026 07:56:00 -0400

si-local-file:///var/storage/secattach/20260806/26879039.html

Form 8-K Viatris Inc For: Aug 06

Thu, 06 Aug 2026 07:56:00 -0400

si-local-file:///var/storage/secattach/20260806/26879039.html

Viatris Inc (VTRS) Tops Q2 EPS by 8c; offers guidance

Thu, 06 Aug 2026 07:01:56 -0400

Viatris Inc (NASDAQ: VTRS) reported Q2 EPS of $0.69, $0.08 better than the analyst estimate of $0.61. Revenue for the quarter came in at $3.76 billion versus the consensus estimate of $3.67 billion.

GUIDANCE:

Viatris Inc sees FY2026 EPS of $2.45-$2.59, versus the consensus of $2.45. Viatris Inc sees FY2026 revenue of $14.55-14.95 billion, versus the consensus of $14.781 billion.

For earnings history and earnings-related data on Viatris Inc (VTRS) click here.

Viatris Inc (VTRS) Tops Q2 EPS by 8c; offers guidance

Thu, 06 Aug 2026 07:01:56 -0400

Viatris Inc (NASDAQ: VTRS) reported Q2 EPS of $0.69, $0.08 better than the analyst estimate of $0.61. Revenue for the quarter came in at $3.76 billion versus the consensus estimate of $3.67 billion.

GUIDANCE:

Viatris Inc sees FY2026 EPS of $2.45-$2.59, versus the consensus of $2.45. Viatris Inc sees FY2026 revenue of $14.55-14.95 billion, versus the consensus of $14.781 billion.

For earnings history and earnings-related data on Viatris Inc (VTRS) click here.

Viatris Reports Second-Quarter 2026 Financial Results

Thu, 06 Aug 2026 06:59:00 -0400

Delivers Total Revenues of $3.8 Billion, Representing 5% Reported Growth Compared to Second Quarter 2025 and a U.S. GAAP Net Loss of $119 Million

Total Revenues Were Up 3.5% Operationally Compared to Second Quarter 2025

Adjusted EBITDA was $1.2 Billion, Up 8% Operationally Compared to Second Quarter 2025

Advances Key Pipeline Milestones, Including U.S. FDA Approval of Gwyn Lo^TM

Announces Sale of Global Rights to Tyrvaya^®

Returns Approximately $550 Million of Capital to Shareholders, Including Through Share Repurchases; Reduces Gross Leverage Ratio to 2.9x

Raises 2026 Financial Guidance Midpoints for All Metrics [1]

Viatris Reports Second-Quarter 2026 Financial Results

Thu, 06 Aug 2026 06:59:00 -0400

Delivers Total Revenues of $3.8 Billion, Representing 5% Reported Growth Compared to Second Quarter 2025 and a U.S. GAAP Net Loss of $119 Million

Total Revenues Were Up 3.5% Operationally Compared to Second Quarter 2025

Adjusted EBITDA was $1.2 Billion, Up 8% Operationally Compared to Second Quarter 2025

Advances Key Pipeline Milestones, Including U.S. FDA Approval of Gwyn Lo^TM

Announces Sale of Global Rights to Tyrvaya^®

Returns Approximately $550 Million of Capital to Shareholders, Including Through Share Repurchases; Reduces Gross Leverage Ratio to 2.9x

Raises 2026 Financial Guidance Midpoints for All Metrics [1]

Viatris Reports Second-Quarter 2026 Financial Results

Thu, 06 Aug 2026 06:59:00 -0400

Delivers Total Revenues of $3.8 Billion, Representing 5% Reported Growth Compared to Second Quarter 2025 and a U.S. GAAP Net Loss of $119 Million

Total Revenues Were Up 3.5% Operationally Compared to Second Quarter 2025

Adjusted EBITDA was $1.2 Billion, Up 8% Operationally Compared to Second Quarter 2025

Advances Key Pipeline Milestones, Including U.S. FDA Approval of Gwyn Lo^TM

Announces Sale of Global Rights to Tyrvaya^®

Returns Approximately $550 Million of Capital to Shareholders, Including Through Share Repurchases; Reduces Gross Leverage Ratio to 2.9x

Raises 2026 Financial Guidance Midpoints for All Metrics [1]

Viatris Reports Second-Quarter 2026 Financial Results

Thu, 06 Aug 2026 06:59:00 -0400

Delivers Total Revenues of $3.8 Billion, Representing 5% Reported Growth Compared to Second Quarter 2025 and a U.S. GAAP Net Loss of $119 Million

Total Revenues Were Up 3.5% Operationally Compared to Second Quarter 2025

Adjusted EBITDA was $1.2 Billion, Up 8% Operationally Compared to Second Quarter 2025

Advances Key Pipeline Milestones, Including U.S. FDA Approval of Gwyn Lo^TM

Announces Sale of Global Rights to Tyrvaya^®

Returns Approximately $550 Million of Capital to Shareholders, Including Through Share Repurchases; Reduces Gross Leverage Ratio to 2.9x

Raises 2026 Financial Guidance Midpoints for All Metrics [1]

Viatris Reports Second-Quarter 2026 Financial Results

Thu, 06 Aug 2026 06:59:00 -0400

Delivers Total Revenues of $3.8 Billion, Representing 5% Reported Growth Compared to Second Quarter 2025 and a U.S. GAAP Net Loss of $119 Million

Total Revenues Were Up 3.5% Operationally Compared to Second Quarter 2025

Adjusted EBITDA was $1.2 Billion, Up 8% Operationally Compared to Second Quarter 2025

Advances Key Pipeline Milestones, Including U.S. FDA Approval of Gwyn Lo^TM

Announces Sale of Global Rights to Tyrvaya^®

Returns Approximately $550 Million of Capital to Shareholders, Including Through Share Repurchases; Reduces Gross Leverage Ratio to 2.9x

Raises 2026 Financial Guidance Midpoints for All Metrics [1]

Viatris Reports Second-Quarter 2026 Financial Results

Thu, 06 Aug 2026 06:59:00 -0400

Delivers Total Revenues of $3.8 Billion, Representing 5% Reported Growth Compared to Second Quarter 2025 and a U.S. GAAP Net Loss of $119 Million

Total Revenues Were Up 3.5% Operationally Compared to Second Quarter 2025

Adjusted EBITDA was $1.2 Billion, Up 8% Operationally Compared to Second Quarter 2025

Advances Key Pipeline Milestones, Including U.S. FDA Approval of Gwyn Lo^TM

Announces Sale of Global Rights to Tyrvaya^®

Returns Approximately $550 Million of Capital to Shareholders, Including Through Share Repurchases; Reduces Gross Leverage Ratio to 2.9x

Raises 2026 Financial Guidance Midpoints for All Metrics [1]

Viatris Reports Second-Quarter 2026 Financial Results

Thu, 06 Aug 2026 06:59:00 -0400

Delivers Total Revenues of $3.8 Billion, Representing 5% Reported Growth Compared to Second Quarter 2025 and a U.S. GAAP Net Loss of $119 Million

Total Revenues Were Up 3.5% Operationally Compared to Second Quarter 2025

Adjusted EBITDA was $1.2 Billion, Up 8% Operationally Compared to Second Quarter 2025

Advances Key Pipeline Milestones, Including U.S. FDA Approval of Gwyn Lo^TM

Announces Sale of Global Rights to Tyrvaya^®

Returns Approximately $550 Million of Capital to Shareholders, Including Through Share Repurchases; Reduces Gross Leverage Ratio to 2.9x

Raises 2026 Financial Guidance Midpoints for All Metrics [1]

Viatris Reports Second-Quarter 2026 Financial Results

Thu, 06 Aug 2026 06:59:00 -0400

Delivers Total Revenues of $3.8 Billion, Representing 5% Reported Growth Compared to Second Quarter 2025 and a U.S. GAAP Net Loss of $119 Million

Total Revenues Were Up 3.5% Operationally Compared to Second Quarter 2025

Adjusted EBITDA was $1.2 Billion, Up 8% Operationally Compared to Second Quarter 2025

Advances Key Pipeline Milestones, Including U.S. FDA Approval of Gwyn Lo^TM

Announces Sale of Global Rights to Tyrvaya^®

Returns Approximately $550 Million of Capital to Shareholders, Including Through Share Repurchases; Reduces Gross Leverage Ratio to 2.9x

Raises 2026 Financial Guidance Midpoints for All Metrics [1]

Viatris Reports Second-Quarter 2026 Financial Results

Thu, 06 Aug 2026 06:59:00 -0400

Delivers Total Revenues of $3.8 Billion, Representing 5% Reported Growth Compared to Second Quarter 2025 and a U.S. GAAP Net Loss of $119 Million

Total Revenues Were Up 3.5% Operationally Compared to Second Quarter 2025

Adjusted EBITDA was $1.2 Billion, Up 8% Operationally Compared to Second Quarter 2025

Advances Key Pipeline Milestones, Including U.S. FDA Approval of Gwyn Lo^TM

Announces Sale of Global Rights to Tyrvaya^®

Returns Approximately $550 Million of Capital to Shareholders, Including Through Share Repurchases; Reduces Gross Leverage Ratio to 2.9x

Raises 2026 Financial Guidance Midpoints for All Metrics [1]

Viatris Reports Second-Quarter 2026 Financial Results

Thu, 06 Aug 2026 06:59:00 -0400

Delivers Total Revenues of $3.8 Billion, Representing 5% Reported Growth Compared to Second Quarter 2025 and a U.S. GAAP Net Loss of $119 Million

Total Revenues Were Up 3.5% Operationally Compared to Second Quarter 2025

Adjusted EBITDA was $1.2 Billion, Up 8% Operationally Compared to Second Quarter 2025

Advances Key Pipeline Milestones, Including U.S. FDA Approval of Gwyn Lo^TM

Announces Sale of Global Rights to Tyrvaya^®

Returns Approximately $550 Million of Capital to Shareholders, Including Through Share Repurchases; Reduces Gross Leverage Ratio to 2.9x

Raises 2026 Financial Guidance Midpoints for All Metrics [1]

Viatris Reports Second-Quarter 2026 Financial Results

Thu, 06 Aug 2026 06:59:00 -0400

Delivers Total Revenues of $3.8 Billion, Representing 5% Reported Growth Compared to Second Quarter 2025 and a U.S. GAAP Net Loss of $119 Million

Total Revenues Were Up 3.5% Operationally Compared to Second Quarter 2025

Adjusted EBITDA was $1.2 Billion, Up 8% Operationally Compared to Second Quarter 2025

Advances Key Pipeline Milestones, Including U.S. FDA Approval of Gwyn Lo^TM

Announces Sale of Global Rights to Tyrvaya^®

Returns Approximately $550 Million of Capital to Shareholders, Including Through Share Repurchases; Reduces Gross Leverage Ratio to 2.9x

Raises 2026 Financial Guidance Midpoints for All Metrics [1]

Viatris Reports Second-Quarter 2026 Financial Results

Thu, 06 Aug 2026 06:59:00 -0400

Delivers Total Revenues of $3.8 Billion, Representing 5% Reported Growth Compared to Second Quarter 2025 and a U.S. GAAP Net Loss of $119 Million

Total Revenues Were Up 3.5% Operationally Compared to Second Quarter 2025

Adjusted EBITDA was $1.2 Billion, Up 8% Operationally Compared to Second Quarter 2025

Advances Key Pipeline Milestones, Including U.S. FDA Approval of Gwyn Lo^TM

Announces Sale of Global Rights to Tyrvaya^®

Returns Approximately $550 Million of Capital to Shareholders, Including Through Share Repurchases; Reduces Gross Leverage Ratio to 2.9x

Raises 2026 Financial Guidance Midpoints for All Metrics [1]

StreetInsider.com News Articles

Form 4 Viatris Inc For: Aug 15 Filed by: Enrietti Andrew

Form 4 Viatris Inc For: Aug 15 Filed by: Enrietti Andrew

Form SCHEDULE 13G/A Viatris Inc Filed by: DAVIS SELECTED ADVISERS

Form SCHEDULE 13G/A Viatris Inc Filed by: DAVIS SELECTED ADVISERS

Viatris Inc (VTRS) spreader of August 17 and January 15 puts

Form 10-Q Viatris Inc For: Jun 30

Form 10-Q Viatris Inc For: Jun 30

Form SCHEDULE 13G Viatris Inc Filed by: FMR LLC

Form SCHEDULE 13G Viatris Inc Filed by: FMR LLC

Form 8-K Viatris Inc For: Aug 06

Form 8-K Viatris Inc For: Aug 06

Viatris Inc (VTRS) Tops Q2 EPS by 8c; offers guidance

Viatris Inc (VTRS) Tops Q2 EPS by 8c; offers guidance

Viatris Reports Second-Quarter 2026 Financial Results

Viatris Reports Second-Quarter 2026 Financial Results

Viatris Reports Second-Quarter 2026 Financial Results

Viatris Reports Second-Quarter 2026 Financial Results

Viatris Reports Second-Quarter 2026 Financial Results

Viatris Reports Second-Quarter 2026 Financial Results

Viatris Reports Second-Quarter 2026 Financial Results

Viatris Reports Second-Quarter 2026 Financial Results

Viatris Reports Second-Quarter 2026 Financial Results

Viatris Reports Second-Quarter 2026 Financial Results

Viatris Reports Second-Quarter 2026 Financial Results

Viatris Reports Second-Quarter 2026 Financial Results